Info@ThinkPinkRocks.com

EMA validates Synageva’s sebelipase alfa MAA for LAL Deficiency

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare disorders, today announced validation by the European Medicines Agency of the Marketing Authorization Application for sebelipase alfa for LAL Deficiency.

Read More:
EMA validates Synageva’s sebelipase alfa MAA for LAL Deficiency

Share

Leave a Reply

Solve : *
2 + 21 =